Pfizer Inc. logo
Pfizer Inc. (PFE)
Compare

PFE Cash Flow Statement

Operating, investing, and financing cash flow analysis

PFE Quarterly Cash Flow Statement (USD)

Quarterly ReportTTM
03/29/2026
12/31/2025
09/28/2025
06/29/2025
03/30/2025
03/29/2025
12/31/2024
09/29/2024
Cash from Operations (CFO)
11.985B2.615B5.349B4.603B-582.000M2.335B6.721B6.714B
7.491B2.688B-1.648B3.541B2.910B2.967B403.000M4.473B
Depreciation & Amortization
6.157B1.183B1.687B1.662B1.625B1.618B1.791B1.755B
676.000M272.000M0.00201.000M203.000M170.000M177.000M274.000M
Change in Accounts Receivable
50.797B12.585B11.874B14.260B12.078B0.0011.845B11.463B14.451B
Change in Inventory
Change in Accounts Payable
Change in Working Capital
1.741B-1.732B1.590B-36.000M1.919B-1.919B2.926B879.000M
Cash from Investing
-2.501B-436.000M-845.000M-602.000M-618.000M-564.000M-917.000M-651.000M
-13.238B0.00-6.927B0.00-6.311B6.311B3.549B0.00
Cash from Financing
Debt Repayment
0.000.000.000.000.000.000.000.00
-9.779B-2.445B-2.445B-2.444B-2.445B-2.437B-2.380B-2.380B
9.484B2.179B4.504B4.001B-1.200B1.771B5.804B6.063B
Net Change in Cash
275.000M563.000M-201.000M-300.000M213.000M374.000M-45.000M40.000M

PFE Annual Cash Flow Statement (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Cash from Operations (CFO)
11.705B12.744B8.700B29.267B32.580B14.403B12.588B15.827B
7.770B8.020B2.133B31.365B22.147B9.159B16.273B11.153B
Depreciation & Amortization
4.905B7.013B6.290B5.064B5.191B4.681B5.795B6.384B
0.00877.000M525.000M872.000M1.182B756.000M718.000M949.000M
Change in Accounts Receivable
11.874B11.463B11.566B10.952B11.479B7.913B6.772B8.025B
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-5.354B-3.066B-2.172B-4.456B12.804B-275.000M-4.031B-926.000M
Cash from Investing
-2.629B-2.909B-3.907B-3.236B-2.711B-2.791B-2.594B-2.196B
-6.927B7.040B-43.430B-22.997B-12.000M-621.000M-10.861B154.000M
Cash from Financing
Debt Repayment
0.000.000.00-2.000B0.000.00-8.865B-12.198B
-9.771B-9.512B-9.247B-8.983B-8.729B-8.440B-8.043B-7.978B
9.076B9.835B4.793B26.031B29.869B11.612B9.994B13.631B
Net Change in Cash
99.000M-1.810B2.449B-1.515B158.000M475.000M-50.000M-206.000M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

New York City, NY
81,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Albert Bourla